Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mach7 TechnologiesASX:M7T +1.79%26 3-1 Month Momentum % is 16.98% as of Aug. 07, 2026. GuruFocus rates ASX:M7T with a GF Score™ of 26/100 and a GF Value™ of A$0.86 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 674 Healthcare Providers & Services companies, Mach7 Technologies ranks better than 84.42% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-07), Mach7 Technologies's 3-1 Month Momentum % is 16.98%.
The industry rank for Mach7 Technologies's 3-1 Month Momentum % or its related term are showing as below:
ASX:M7T's 3-1 Month Momentum % is ranked better than 84.42% of 674
companies
in the Healthcare Providers & Services industry
Industry Median: -2.265
vs ASX:M7T: 16.98
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Mach7 Technologies 3-1 Month Momentum % Related Terms
ASX:M7T vs VEEV, BTSG, HQY: 3-1 Month Momentum % Comparison
For the Health Information Services subindustry, Mach7 Technologies's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mach7 Technologies 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mach7 Technologies's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Mach7 Technologies's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mach7 Technologies (ASX:M7T) has a 3-1 Month Momentum % of 16.98% as of Aug. 07, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Mach7 Technologies and its competitors. According to the industry distribution chart, Mach7 Technologies ranks #105 out of 674 companies in the Healthcare Providers & Services industry, placing it in the top 15.6%.
Is Mach7 Technologies' 3-1 Month Momentum % too high?
Mach7 Technologies' current 3-1 Month Momentum % is 16.98%. Based on the distribution chart, Mach7 Technologies ranks #105 out of 674 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Mach7 Technologies has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mach7 Technologies' 3-1 Month Momentum % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Mach7 Technologies ranks #105 out of 674 companies for 3-1 Month Momentum %. This places Mach7 Technologies in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
A good 3-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Mach7 Technologies and its competitors. Mach7 Technologies's current 3-1 Month Momentum % is 16.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mach7 Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mach7 Technologies (ASX:M7T) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.86, compared to a current price of A$0.29 — trading 66.9% below its estimated fair value. The current 3-1 Month Momentum % is 16.98%. Mach7 Technologies' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Mach7 Technologies (ASX:M7T), the current 3-1 Month Momentum % is 16.98% as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mach7 Technologies (ASX:M7T) Overvalued in 2026?
Based on GuruFocus' analysis, Mach7 Technologies stock appears to be undervalued.
The current stock price of A$0.29 is trading 66.9% below its estimated GF Value™ of A$0.86.
GuruFocus considers Mach7 Technologies to be Possible Value Trap.
Key valuation signals for ASX:M7T:
3-1 Month Momentum %: 16.98%
GF Value™: A$0.86 vs. price of A$0.29 (66.9% below fair value)
No single metric tells the full story. See the ASX:M7T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mach7 Technologies Ltd is a healthcare software company focused on enterprise imaging infrastructure. The company's vendor neutral platform enables health systems to manage, access, and exchange medical imaging data across departments, sites, and vendors. It serves across North America, Asia-Pacific, and the Middle East, with deployments ranging from academic medical centres to multi-site health networks. A substantial part of revenue is derived in the form of Subscription revenue. Geographically, it derives a majority of its revenue from North America.
26GF Score
Get the complete analysis for ASX:M7T
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:M7T has been successfully added to your 
